Original Source(s)
Related Content
FDA Expands Pediatric Roflumilast Use
The expanded indication is supported by pharmacokinetic, safety, tolerability, exploratory efficacy, and long-term safety data from studies in children aged 2 to 5 years.
June 30, 2026
-
3 min
FDA approves first therapy for symptomatic dermographism
The oral BTK inhibitor produced a complete hive response in 29.3% of treated patients at week 12.
by Teraya Smith
October 7, 2026
-
2 min